MedTrace Logo

Investigate the Effectiveness of KEFPEP® on Regulating High Blood Pressure

NCT06393621 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-05-01

No results posted yet for this study

Summary

To assess the ability of KEFPEP® to reduce blood pressure

Conditions

  • Prehypertension

Interventions

DIETARY_SUPPLEMENT

KEFPEP®

Twice daily (one pack before breakfast and the other before dinner)

OTHER

Placebo

Twice daily (one pack before breakfast and the other before dinner)

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • National Chung Hsing University

    lead OTHER

Principal Investigators

  • Jen-Kuang Lee, MD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-26
Primary Completion
2023-04-18
Completion
2023-08-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06393621 on ClinicalTrials.gov